A Phase 2b, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of AR882 Versus Placebo in Gout Patients
Latest Information Update: 02 Jan 2024
At a glance
- Drugs AR 882 (Primary)
- Indications Gout
- Focus Therapeutic Use
- Sponsors Arthrosi Therapeutics
- 15 Nov 2023 Results of an analysis reporting efficacy and safety based on various demographics and baseline characteristics following 12 weeks of treatment presented at the ACR Convergence 2023
- 15 Nov 2023 Results assessing renal safety of AR882 uric acid excretion profiles across multiple studies (phase 1 studies and phase 2b) presented at the ACR Convergence 2023
- 15 Nov 2023 Results assessing pharmacokinetics and pharmacodynamics AR882 following 12-Week treatment in patients with gout presented at the ACR Convergence 2023